Showing results (261-270 of 274) with videos related to

Sort By:
Pageof 28
Journal of Medicinal Chemistry|August 12, 2024
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug DesignTaylor R Quinn, Kathryn A Giblin, Clare Thomson, et al.
Journal of Medicinal Chemistry|September 18, 2024
Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 InhibitorsSimon C C Lucas, J Henry Blackwell, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor ImmunityJeffrey A Boerth, Alex J Chinn, Marianne Schimpl, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacologyJeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
ACS Medicinal Chemistry Letters|June 19, 2024
Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library ScreenSimon C C Lucas, J Henry Blackwell, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Pageof 28